Surgery Partners Inc’s filing revealed that its Officer Jennifer Baldock acquired Company’s shares for reported $72111.0 on Mar 10 ’25. In the deal valued at $23.97 per share,3,008 shares were bought.
Then, Marissa Brittenham bought 3,156 shares, generating $76,031 in total proceeds.
Before that, Danielle Burkhalter bought 1,240 shares. Surgery Partners Inc shares valued at $29,935 were divested by the Officer at a price of $24.14 per share.
BofA Securities initiated its Surgery Partners Inc [SGRY] rating to a Buy in a research note published on December 16, 2024; the price target was $30. A number of analysts have revised their coverage, including UBS’s analysts, who began to cover the stock in mid October with a ‘”a Buy”‘ rating. KeyBanc Capital Markets began covering SGRY with “Sector weight” recommendation on October 11, 2024. Macquarie started covering the stock on June 28, 2024. It rated SGRY as “an Outperform”.
Price Performance Review of SGRY
On Tuesday, Surgery Partners Inc [NASDAQ:SGRY] saw its stock fall -0.13% to $23.63. Over the last five days, the stock has lost -0.71%. Surgery Partners Inc shares have risen nearly 11.62% since the year began. Nevertheless, the stocks have fallen -21.26% over the past one year. While a 52-week high of $33.97 was reached on 02/14/25, a 52-week low of $19.50 was recorded on 01/14/25. SMA at 50 days reached $23.35, while 200 days put it at $26.55.
Levels Of Support And Resistance For SGRY Stock
The 24-hour chart illustrates a support level at 23.43, which if violated will result in even more drops to 23.23. On the upside, there is a resistance level at 23.81. A further resistance level may holdings at 23.99. The Relative Strength Index (RSI) on the 14-day chart is 40.99, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.69, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 86.40%. Stochastics %K at 18.42% indicates the stock is a buying.
The most recent change occurred on March 06, 2024 when Barclays began covering the stock and recommended ‘”an Equal weight”‘ rating along with a $35 price target.
